← Back to Clinical Trials
Recruiting NCT07774078

NCT07774078 Effectiveness and Utility of Telemonitoring in Improving the Glycaemic Control of Diabetes Mellitus Tunisian Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07774078
Status Recruiting
Phase
Sponsor University of Monastir
Condition Diabete Mellitus
Study Type INTERVENTIONAL
Enrollment 260 participants
Start Date 2024-08-01
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Telemonitoring groupUsual Care Group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 260 participants in total. It began in 2024-08-01 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study aims to evaluate the impact of a telemonitoring system on glycemic control in patients with diabetes in Tunisia. Participants in the intervention group will receive remote diabetes management through a dedicated mobile application and web platform, while the control group will receive standard diabetes care. The primary objective is to determine the effectiveness of telemonitoring in improving glycemic control, as assessed by changes in glycated hemoglobin (HbA1c) and blood glucose levels.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of diabetes mellitus with HbA1c between 7% and 10%. * Stable antidiabetic treatment for at least 4 weeks prior to enrollment. Exclusion Criteria: * Serum creatinine \>200 µmol/L. * Acute coronary syndrome or stroke. * Dementia. * Pregnancy. * Inability to participate in or comply with the telemonitoring intervention. * Severe diabetic retinopathy.

Contact & Investigator

Central Contact

Nouira Semir

✉ semir.nouira@rns.tn

📞 0021673106046

Frequently Asked Questions

Who can join the NCT07774078 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Diabete Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07774078 currently recruiting?

Yes, NCT07774078 is actively recruiting participants. Contact the research team at semir.nouira@rns.tn for enrollment information.

Where is the NCT07774078 trial being conducted?

This trial is being conducted at Monastir, Tunisia.

Who is sponsoring the NCT07774078 clinical trial?

NCT07774078 is sponsored by University of Monastir. The trial plans to enroll 260 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology